ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 89 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $345,840 | -36.1% | 72,050 | -0.1% | 0.00% | – |
| Q2 2023 | $541,395 | +73.5% | 72,090 | +4.4% | 0.00% | – |
| Q1 2023 | $311,993 | -60.3% | 69,025 | -0.9% | 0.00% | – |
| Q4 2022 | $785,057 | +17.7% | 69,659 | -0.1% | 0.00% | – |
| Q3 2022 | $667,000 | +30.8% | 69,720 | +10.5% | 0.00% | – |
| Q2 2022 | $510,000 | -59.3% | 63,100 | -14.8% | 0.00% | – |
| Q1 2022 | $1,252,000 | -25.6% | 74,093 | -5.4% | 0.00% | – |
| Q4 2021 | $1,683,000 | -74.7% | 78,294 | -13.1% | 0.00% | -100.0% |
| Q3 2021 | $6,655,000 | +67.7% | 90,112 | +24.1% | 0.00% | 0.0% |
| Q2 2021 | $3,969,000 | -17.5% | 72,602 | +11.2% | 0.00% | 0.0% |
| Q1 2021 | $4,813,000 | -6.3% | 65,272 | +9.6% | 0.00% | 0.0% |
| Q4 2020 | $5,136,000 | +473.2% | 59,574 | +151.1% | 0.00% | – |
| Q3 2020 | $896,000 | – | 23,729 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $46,559,640 | 13.20% |
| Vivo Capital, LLC | 4,220,048 | $20,256,230 | 2.22% |
| Logos Global Management LP | 1,000,000 | $4,800,000 | 0.64% |
| Orbimed Advisors | 2,871,000 | $13,780,800 | 0.29% |
| Redmile Group, LLC | 1,283,289 | $6,159,787 | 0.29% |
| BRAIDWELL LP | 1,249,900 | $5,999,520 | 0.19% |
| Cormorant Asset Management, LP | 612,079 | $2,937,979 | 0.17% |
| Nan Fung Group Holdings Ltd | 41,950 | $201,360 | 0.16% |
| Forefront Analytics, LLC | 13,769 | $66,092 | 0.04% |
| CORNERCAP INVESTMENT COUNSEL INC | 35,071 | $168,341 | 0.03% |